7XJH image
Deposition Date 2022-04-18
Release Date 2022-05-04
Last Version Date 2025-07-02
Entry Detail
PDB ID:
7XJH
Title:
Isoproterenol-activated dog beta3 adrenergic receptor
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Rattus norvegicus (Taxon ID: 10116)
Bos taurus (Taxon ID: 9913)
unidentified (Taxon ID: 32644)
Canis lupus familiaris (Taxon ID: 9615)
Method Details:
Experimental Method:
Resolution:
3.30 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
Gene (Uniprot):GNAS
Chain IDs:A
Chain Length:380
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Gene (Uniprot):Gnb1
Chain IDs:B
Chain Length:344
Number of Molecules:1
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Gene (Uniprot):GNG2
Chain IDs:C (auth: G)
Chain Length:68
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Molecule:Nanobody-35
Chain IDs:D (auth: N)
Chain Length:137
Number of Molecules:1
Biological Source:unidentified
Polymer Type:polypeptide(L)
Molecule:Beta-3 adrenergic receptor
Gene (Uniprot):ADRB3
Chain IDs:E (auth: R)
Chain Length:395
Number of Molecules:1
Biological Source:Canis lupus familiaris
Ligand Molecules
Primary Citation
Cryo-EM structure of the beta 3-adrenergic receptor reveals the molecular basis of subtype selectivity.
Mol.Cell 81 3205 3215.e5 (2021)
PMID: 34314699 DOI: 10.1016/j.molcel.2021.06.024

Abstact

The β3-adrenergic receptor (β3AR) is predominantly expressed in adipose tissue and urinary bladder and has emerged as an attractive drug target for the treatment of type 2 diabetes, obesity, and overactive bladder (OAB). Here, we report the cryogenic electron microscopy structure of the β3AR-Gs signaling complex with the selective agonist mirabegron, a first-in-class drug for OAB. Comparison of this structure with the previously reported β1AR and β2AR structures reveals a receptor activation mechanism upon mirabegron binding to the orthosteric site. Notably, the narrower exosite in β3AR creates a perpendicular pocket for mirabegron. Mutational analyses suggest that a combination of both the exosite shape and the amino-acid-residue substitutions defines the drug selectivity of the βAR agonists. Our findings provide a molecular basis for βAR subtype selectivity, allowing the design of more-selective agents with fewer adverse effects.

Legend

Protein

Chemical

Disease

Primary Citation of related structures